ProQR Therapeutics (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by Brokerages

Shares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have received an average rating of "Buy" from the eight ratings firms that are covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $8.00.

A number of research firms have recently weighed in on PRQR. Cantor Fitzgerald began coverage on ProQR Therapeutics in a report on Tuesday, April 29th. They issued an "overweight" rating and a $8.00 target price on the stock. Evercore ISI began coverage on ProQR Therapeutics in a report on Tuesday, April 29th. They issued an "outperform" rating and a $5.00 target price on the stock. HC Wainwright raised their target price on ProQR Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a report on Friday, March 14th. Chardan Capital reiterated a "buy" rating and set a $4.00 price target on shares of ProQR Therapeutics in a report on Friday, March 14th. Finally, Citigroup upgraded ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 target price on the stock in a research note on Monday, March 10th.

ProQR Therapeutics Stock Down 1.1%

PRQR traded down $0.02 during trading on Thursday, reaching $1.79. 221,646 shares of the stock traded hands, compared to its average volume of 636,415. The stock's 50-day moving average is $1.49 and its 200 day moving average is $2.16. ProQR Therapeutics has a 12 month low of $1.07 and a 12 month high of $4.62. The stock has a market capitalization of $188.33 million, a PE ratio of -5.59 and a beta of 0.35.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.02). ProQR Therapeutics had a negative net margin of 134.31% and a negative return on equity of 71.58%. The company had revenue of $4.89 million for the quarter, compared to analyst estimates of $4.90 million. As a group, equities research analysts anticipate that ProQR Therapeutics will post -0.31 EPS for the current year.

Hedge Funds Weigh In On ProQR Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE increased its stake in ProQR Therapeutics by 11.8% in the 4th quarter. Bank of America Corp DE now owns 81,784 shares of the biopharmaceutical company's stock worth $217,000 after acquiring an additional 8,621 shares during the last quarter. Jane Street Group LLC bought a new position in shares of ProQR Therapeutics during the 4th quarter valued at about $30,000. Squarepoint Ops LLC increased its position in shares of ProQR Therapeutics by 16.3% during the 4th quarter. Squarepoint Ops LLC now owns 83,114 shares of the biopharmaceutical company's stock valued at $220,000 after purchasing an additional 11,623 shares during the last quarter. Invesco Ltd. bought a new position in shares of ProQR Therapeutics during the 4th quarter valued at about $32,000. Finally, OneDigital Investment Advisors LLC increased its position in shares of ProQR Therapeutics by 45.5% during the 1st quarter. OneDigital Investment Advisors LLC now owns 40,000 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 12,500 shares during the last quarter. 32.65% of the stock is currently owned by institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).